Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560703 · ClinicalTrials.gov registry record · Phase 2
Treatment of Patients With Blepharitis and Facial Rosacea
A Phase 2 study of Dry Eye and Blepharitis, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT00560703 is a Phase 2 study of Dry Eye and Blepharitis that has completed, run by Galderma R&D. The registered enrollment target is 70 participants, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (26% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT00560703, a Phase 2 study of Dry Eye and Blepharitis, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
Conditions Studied
Interventions
- DRUG placebo
- DRUG COL-101 (doxycycline, USP) capsules
Study Locations (8)
Arkansas
- Pleasant Valley Ophthalmology - Little Rock
Florida
- Warren Scherer, MD - Naples
Kentucky
- Kentucky Lions Eye Center - Louisville
Missouri
- Washington University School of Medicine - St Louis
New York
- Marguerite McDonald, MD - Lynbrook
Oklahoma
- Dean McGee Eye Institute - Oklahoma City
Pennsylvania
- Anita Nevyas-Wallace, MD - Bala-Cynwyd
Utah
- Tanner Clinic - Layton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00560703
The ClinicalTrials.gov registry entry for NCT00560703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (26% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00560703 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arkansas, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00560703 about?
NCT00560703 is a clinical study titled "Treatment of Patients With Blepharitis and Facial Rosacea". To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
What is the current status of trial NCT00560703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2007-11. Estimated completion is 2009-07.
What conditions does trial NCT00560703 study?
This clinical trial studies the following conditions: Dry Eye, Blepharitis, Meibomianitis.
What interventions are being tested in trial NCT00560703?
The interventions under investigation include: placebo (DRUG), COL-101 (doxycycline, USP) capsules (DRUG).
Who is sponsoring clinical trial NCT00560703?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00560703 being conducted?
This trial has 8 study locations across Arkansas, Florida, Kentucky, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.